07.05.2024 - May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will .
08.01.2024 - Reported $1.2 billion in preliminary full-year 2023 global net product sales Submitted sBLA to FDA for VYVGART Hytrulo for CIDP with priority review voucher (PRV); if approved, launch expected mid-2024 Reported positive data from Phase 2 ARDA . Seite 1
02.01.2024 - Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will .
21.09.2023 - VYVGARTⓇ is the first-and-only neonatal Fc receptor (FcRn) blocker authorized for sale in Canada Approval based on the positive Phase 3 ADAPT trial (p